Loading...

COVID‑19 Alert: Stay home if you feel unwell. If you have a fever, cough and difficulty breathing, seek medical attention. Follow the directions of your local health authority. Source WHO

We have a lockdown, "Working from HOME" Please reach out for any queries at: help@alliedmarketresearch.com & Int'l : +1-503-894-6022, (UK) : +44-845-528-1300

New

Stem Cell Umbilical Cord Blood Market by Storage Service (Public Cord Blood Banks, Private Cord Blood Banks, and Hybrid Cord Blood Banks), Therapeutics (Cancer, Diabetes, Blood Diseases, Immune Disorders, Metabolic Disorders, and Other Diseases), and Application( Transplant Medicine and Regenerative Medicine): Global Opportunity Analysis and Industry Forecast, 2020–2027

A00037
Pages: 209
Aug 2020 | 29409 Views
 
Author(s) : Ankita Sonar & Komal Urde , Onkar Sumant
Tables: 112
Charts: 12
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Stem Cell Umbilical Cord Blood Market

Request Now !

The global stem cell umbilical cord blood market was valued at $3,110.8 million in 2019, and is projected to reach $10,135.20 million by 2027, registering a CAGR of 16.9% from 2020 to 2027. 

Presently, the global stem cell market dominates the healthcare industry with its reliable and cost-effective methods of treatment and fewer side effects. The umbilical cord blood stem cell segmentis one of the potential segments of the stem cell market, which is projected to grow in the future. Cord blood is one of the rich sources of stem cells, which are treated as waste after pregnancy or childbirth; however, this blood has huge potential to treat chronic diseases such as cancer, diabetes, blood diseases, and immune diseases. 

Get more information on this report : Request Sample Pages

Currently, more than 80 genetic diseases can be treated with cord bloodas it is a rich source of hematopoietic stem cells. Various governments are supporting the research and clinical trials of cord blood stem cells, which has increased the interest of healthcare companies to invest in research and commercialization of cord blood stem cell therapies. However, competition in the market is intense with companies trying to create brand awareness, therefore, compelling market players to adopt many market-based strategies. These stem cells are the only type of cells that are stored in controlled conditions due to their lower volume and higher cell count. 

Cost structure of the stem cell treatment has a major impact on the growth of the market in developed countries. Stem cells collected from cord blood are used in treatment of many rare diseases that include metabolic diseases and immune diseases. The overall stem cell umbilical cord blood market is growing from clinical applications to commercialization. Companies involved in the research and commercialization of stem cell therapies are adopting approval and clinical trials as their primary strategy and product launch as their secondary strategy to maintain their dominance in the stem cell umbilical cord blood market.

On the basis of storage service, the stem cell umbilical cord blood market is segmented into private cord blood banks, public cord blood banks, and hybrid cord blood banks. The private cord banks segment was the highest contributor to the market, with $1,537 million in 2019, and is estimated to reach $4,765.90 million by 2027, at a CAGR of 15.3% during the forecast period.

By therapeutics, the stem cell umbilical cord blood market is categorized into cancer, diabetes, blood diseases, immune disorders, metabolic disorders, and other diseases. The diabetes segment was the highest contributor to the market, with $794.57 million in 2019, and is estimated to reach $2,655.58 million by 2027, at a CAGR of 16.4% during the forecast period.

By application, the stem cell umbilical cord blood market is categorized into transplant medicine and regenerative medicine. The regenerative medicine segment was the highest contributor to the market, with $1,854.12 million in 2019, and is estimated to reach $5,878.55 million by 2027, at a CAGR of 15.6% during the forecast period.

The stem cell umbilical cord blood market is more lucrative in North America and European countries. Most patents granted for cord blood were from the U.S. and European authorities. North America shared the largest revenue of $1,537.4 million in 2019, however Asia-Pacific is expected to grow at CAGR of 16.7% CAGR during the forecast period.

The companies offering stem cell umbilical cord blood storage services include Cordlife Group Limited, Cord Blood America, Cryo-Cell International, Medipost, Global Cord Blood Corporation, Americord Registry, and Cordvida. 

Global Stem Cell Umblical Cord Blood market Segmentation

The stem cell umbilical cord blood market is segmented on the basis of storage service, therapeutics, application, and region. By type, it is categorized into public cord blood banks, private cord blood banks, and hybrid cord blood banks. On the basis of therapeutics, it is divided into cancer, diabetes, blood diseases, immune disorders, metabolic disorders, and other diseases. By application, it is categorized into transplant medicine and regenerative medicine. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Stem Cell Umbilical Cord Blood Market
By Storage Service

Your browser does not support the canvas element.

Hybrid cord blood banks is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

Segment review

Depending on storage service, the market is categorized into private cord blood banks, public cord blood banks, and hybrid cord blood banks. The private cord blood banks segment dominated the global market in 2019, and is anticipated to continue this trend during the forecast period. The key factors such as rise in use of stem cells to cure diseases and finding accurate match for transfer are expected to drive the growth of this segment.

On the basis of therapeutics, the stem cell umbilical cord blood market is categorized into cancer, diabetes, blood diseases, immune disorders, metabolic disorders, and others. The diabetes segment held a dominant position in the market, accounting for about $ 794.57 million revenue of the global stem cell umbilical cord blood market in 2019. 

Stem Cell Umbilical Cord Blood Market
By Application

Your browser does not support the canvas element.

Regenerative Medicine segment holds a dominant position in 2019

Get more information on this report : Request Sample Pages

By application, the stem cell umbilical cord blood market is categorized into transplant medicine and regenerative medicine. The regenerative medicine segment held a dominant portion in the market, accounting for about $ 1,854.12 revenue of the global stem cell umbilical cord blood market in 2019.

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the global stem cell umbilical cord blood market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers stem cell umbilical cord blood market analysis from 2020to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis on region assists to understand the regional stem cell umbilical cord blood market and facilitate the strategic business planning and determine prevailing opportunities. 
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global stem cell umbilical cord blood market growth.

Key Market Segments

By Storage services 

  • Public Cord Blood Banks
  • Private Cord Blood Banks 
  • Hybrid Cord Blood Banks

By Therapeutics 

  • Cancer
  • Diabetes
  • Blood Diseases
  • Immune Disorders
  • Metabolic Disorders
  • Other Diseases

By Application 

  • Transplant Medicine
  • Regenerative Medicine  

By Region 

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK 
    • Germany 
    • France 
    • Italy
    • Spain 
    • Rest of Europe
  • Asia-Pacific
    • Japan 
    • China
    • Australia 
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil 
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key players in the market

  • Cordlife Group Limited
  • Cord Blood America
  • Cryo-Cell International
  • Medipost
  • Americord Registry
  • Esperite
  • China Cord Blood Corporation
  • LifeCell Inetrnational
  • ViaCord
  • Vita34 AG
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Research methodology

1.3.1.Secondary research
1.3.2.Primary research
1.3.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope

3.1.1.Drivers

3.1.1.1.Diversification of services
3.1.1.2.Genetic testing, fertility, and reproduction assisted services
3.1.1.3.Treatment for chronic diseases
3.1.1.4.Rise in spending capacity and suitable payment plans

3.1.2.Restraints

3.1.2.1.Legal and ethical issues during collection
3.1.2.2.Higher cost of therapies
3.1.2.3.Unavailability of suitable matched donor

3.1.3.Opportunities

3.1.3.1.Advancements in therapeutic applications
3.1.3.2.Rise in funds for public storage

3.1.4.Value chain analysis of stem cell umbilical cord blood market

3.2.Top Player Positioning, 2019

CHAPTER 4:STEM CELL UMBILICAL CORD BLOOD MARKET, BY STORAGE SERIVCES

4.1.Overview

4.1.1.Market size and forecast

4.2.Public Cord Blood Banks

4.2.1.Overview
4.2.2.Key growth trends and opportunities
4.2.3.Market size and forecast
4.2.4.Market analysis, by country

4.3.Private Cord Blood Banks

4.3.1.Overview
4.3.2.Key growth trends and opportunities
4.3.3.Market size and forecast
4.3.4.Market analysis, by country

4.4.Hybrid Cord Blood Banks

4.4.1.Overview
4.4.2.Market size and forecast
4.4.3.Market analysis, by country

CHAPTER 5:STEM CELL UMBILICAL CORD BLOOD MARKET, BY THERAPEUTICS

5.1.Overview

5.1.1.Market size and forecast

5.2.Cancer

5.2.1.Overview
5.2.2.Market size and forecast
5.2.3.Market analysis, by country

5.3.Diabetes

5.3.1.Overview
5.3.2.Market size and forecast
5.3.3.Market analysis, by country

5.4.Blood diseases

5.4.1.Overview
5.4.2.Market size and forecast
5.4.3.Market analysis, by country

5.5.Immune Disorders

5.5.1.Overview
5.5.2.Market size and forecast
5.5.3.Market analysis, by country

5.6.Metabolic Disorders

5.6.1.Overview
5.6.2.Market size and forecast
5.6.3.Market analysis, by country

5.7.Others

5.7.1.Overview
5.7.2.Market size and forecast
5.7.3.Market analysis, by country

CHAPTER 6:STEM CELL UMBILICAL CORD BLOOD MARKET, BY APPLICATION

6.1.Overview

6.1.1.Market size and forecast

6.2.Transplant Medicine

6.2.1.Overview
6.2.2.Market size and forecast
6.2.3.Market analysis, by country

6.3.Regenerative Medicine

6.3.1.Overview
6.3.2.Market size and forecast
6.3.3.Market analysis, by country

CHAPTER 7:STEM CELL UMBILICAL CORD BLOOD MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by country
7.2.3.Market size and forecast, by storage service
7.2.4.Market size and forecast, by therapeutics
7.2.5.Market size and forecast, by application
7.2.6.U.S. 

7.2.6.1.U.S. market size and forecast, by storage service
7.2.6.2.U.S. market size and forecast, by therapeutics
7.2.6.3.U.S. market size and forecast, by application

7.2.7.Canada

7.2.7.1.Canada market size and forecast, by storage service
7.2.7.2.Canada market size and forecast, by therapeutics
7.2.7.3.Canada market size and forecast, by application

7.2.8.Mexico

7.2.8.1.Mexico market size and forecast, by storage service
7.2.8.2.Mexico market size and forecast, by therapeutics
7.2.8.3.Mexico market size and forecast, by application

7.3.Europe

7.3.1.Europe market size and forecast, by country
7.3.2.Europe market size and forecast, by storage service
7.3.3.Europe market size and forecast, by therapeutics
7.3.4.Europe market size and forecast, by application
7.3.5.UK

7.3.5.1.UK market size and forecast, by storage service
7.3.5.2.UK market size and forecast, by therapeutics
7.3.5.3.UK market size and forecast, by application

7.3.6.France

7.3.6.1.France market size and forecast, by storage service
7.3.6.2.France market size and forecast, by storage service
7.3.6.3.France market size and forecast, by therapeutics
7.3.6.4.France market size and forecast, by application

7.3.7.Germany

7.3.7.1.Germany market size and forecast, by storage service
7.3.7.2.Germany market size and forecast, by therapeutics
7.3.7.3.Germany market size and forecast, by application

7.3.8.Italy

7.3.8.1.Italy market size and forecast, by storage service
7.3.8.2.Italy market size and forecast, by therapeutics
7.3.8.3.Italy market size and forecast, by application

7.3.9.Spain

7.3.9.1.Spain market size and forecast, by storage service
7.3.9.2.Spain market size and forecast, by therapeutics
7.3.9.3.Spain market size and forecast, by application

7.3.10.Rest of Europe

7.3.10.1.Rest of Europe market size and forecast, by storage service
7.3.10.2.Rest of Europe market size and forecast, by therapeutics
7.3.10.3.Rest of Europe market size and forecast, by application

7.4.Asia-Pacific

7.4.1.Key market trends and opportunities
7.4.2.Asia-Pacific market size and forecast, by country
7.4.3.Asia-Pacific market size and forecast, by storage service
7.4.4.Asia-Pacific market size and forecast, by therapeutics
7.4.5.Asia-Pacific market size and forecast, by application
7.4.6.Japan

7.4.6.1.Japan market size and forecast, by storage service
7.4.6.2.Japan market size and forecast, by therapeutics
7.4.6.3.Japan market size and forecast, by application

7.4.7.China

7.4.7.1.China market size and forecast, by storage service
7.4.7.2.China market size and forecast, by therapeutics
7.4.7.3.China market size and forecast, by application

7.4.8.India

7.4.8.1.India market size and forecast, by storage service
7.4.8.2.India market size and forecast, by therapeutics
7.4.8.3.India market size and forecast, by application

7.4.9.Rest of Asia-Pacific

7.4.9.1.Rest of Asia-Pacific market size and forecast, by storage service
7.4.9.2.Rest of Asia-Pacific market size and forecast, by therapeutics
7.4.9.3.Rest of Asia-Pacific market size and forecast, by application

7.5.LAMEA

7.5.1.Key market trends and opportunities
7.5.2.LAMEA market size and forecast, by country
7.5.3.LAMEA market size and forecast, by storage service
7.5.4.LAMEA market size and forecast, by therapeutics
7.5.5.LAMEA  market size and forecast, by application
7.5.6.Brazil

7.5.6.1.Brazil market size and forecast, by storage service
7.5.6.2.Brazil market size and forecast, by therapeutics
7.5.6.3.Brazil market size and forecast, by application

7.5.7.South Africa

7.5.7.1.South Africa market size and forecast, by storage service
7.5.7.2.South Africa market size and forecast, by therapeutics
7.5.7.3.South Africa market size and forecast, by application

7.5.8.Saudi Arabia

7.5.8.1.Saudi Arabia market size and forecast, by storage service
7.5.8.2.Saudi Arabia market size and forecast, by therapeutics
7.5.8.3.Saudi Arabia market size and forecast, by application

7.5.9.Rest of LAMEA

7.5.9.1.Rest of LAMEA market size and forecast, by storage service
7.5.9.2.Rest of LAMEA market size and forecast, by therapeutics
7.5.9.3.Rest of LAMEA market size and forecast, by application

CHAPTER 8:COMPANY PROFILES

8.1.Americord Registry LLC

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio

8.2.China Cord Blood Corporation

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Business performance

8.3.Cord Blood America, Inc. 

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments

8.4.Cordlife Group Limited

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments

8.5.Cryo-Cell International, Inc. 

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance

8.6.Esperite N.V. 

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio

8.7.LifeCell International Pvt. Ltd. 

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio

8.8.Medipost Co. Ltd. 

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.ViaCord

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio

8.10.Vita34 AG

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance

LIST OF TABLES

TABLE 01.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 02.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY PUBLIC CORD BLOOD STORAGE, 2019–2027 ($MILLION) 
TABLE 03.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY PRIVATE CORD BLOOD STORAGE, 2019–2027 ($MILLION) 
TABLE 04.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY HYBRID CORD BLOOD STORAGE, 2019–2027 ($MILLION) 
TABLE 05.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS , 2019–2027 ($MILLION) 
TABLE 06.STEM CELL UMBILICIAL CORD BLOOD MARKET FOR CANCER , 2019–2027 ($MILLION) 
TABLE 07.STEM CELL UMBILICIAL CORD BLOOD MARKET FOR DIABETES  2019–2027 ($MILLION) 
TABLE 08.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION) 
TABLE 09.STEM CELL UMBILICIAL CORD BLOOD MARKET FOR IMMUNE DISORDERS, 2019–2027 ($MILLION) 
TABLE 10.STEM CELL UMBILICIAL CORD BLOOD MARKET FOR METABOLIC DISORDERS, 2019–2027 ($MILLION) 
TABLE 11.GLOBAL STEM CELL UMBILICIAL CORD BLOOD MARKET, BY TYPE OF IMMUNE DISORDERS, 2019–2027 ($MILLION) 
TABLE 12.GLOBAL STEM CELL UMBILICIAL CORD BLOOD MARKET FOR OTHERS  2019–2027 ($MILLION) 
TABLE 13.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 14.STEM CELL UMBILICIAL CORD BLOOD MARKET, FOR TRANSPLANT MEDICINE , 2019–2027 ($MILLION) 
TABLE 15.STEM CELL UMBILICIAL CORD BLOOD MARKET,  FOR REGENERATIVE MEDICINE , 2019–2027 ($MILLION) 
TABLE 16.STEM CELL UMBLICIAL CORD BLOOD MARKET, BY REGION, 2019–2027 ($MILLION) 
TABLE 17.NORTH AMERICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY COUNTRY, 2019 –2026 ($MILLION) 
TABLE 18.NORTH AMERICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 19.NORTH AMERICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2026 ($MILLION) 
TABLE 20.NORTH AMERICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2026 ($MILLION) 
TABLE 21.U.S. STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 22.U.S. STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2026 ($MILLION) 
TABLE 23.U.S. STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 24.CANADA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 25.CANADA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION) 
TABLE 26.CANADA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 27.MEXICO STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 28.MEXICO STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION) 
TABLE 29.MEXICO STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 30.EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY COUNTRY, 2019–2027 ($MILLION) 
TABLE 31.EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 32.EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION) 
TABLE 33.EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 34.UK STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 35.UK STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2020 ($MILLION) 
TABLE 36.UK STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 37.FRANCE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 38.FRANCE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION) 
TABLE 39.FRANCE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 40.GERMANY STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 41.GERMANY STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019S–2027 ($MILLION) 
TABLE 42.GERMANY STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 43.ITALY STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 44.ITALY STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION) 
TABLE 45.ITALY STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 46.SPAIN STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 47.SPAIN STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION) 
TABLE 48.SPAIN STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 49.REST OF EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 50.REST OF EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION) 
TABLE 51.REST OF EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 52.ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY COUNTRY, 2019–2027 ($MILLION) 
TABLE 53.ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 54.ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION) 
TABLE 55.ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 56.JAPAN STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 57.JAPAN STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION) 
TABLE 58.JAPAN STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 59.CHINA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 60.CHINA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION) 
TABLE 61.CHINA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 62.INDIA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 63.INDIA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION) 
TABLE 64.INDIA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 65.REST OF ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 66.REST OF ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION) 
TABLE 67.REST OF ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 68.LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY COUNTRY, 2019–2027 ($MILLION) 
TABLE 69.LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 70.LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION) 
TABLE 71.LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 72.BRAZIL STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 73.BRAZIL STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION) 
TABLE 74.BRAZIL STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 75.SOUTH AFRICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 76.SOUTH AFRICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION) 
TABLE 77.SOUTH AFRICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 78.SAUDI ARABIA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 79.SAUDI ARABIA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION) 
TABLE 80.SAUDI ARABIA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 81.REST OF LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION) 
TABLE 82.REST OF LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION) 
TABLE 83.REST OF LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION) 
TABLE 84.AMERICORD REGISTRY LLC: COMPANY SNAPSHOT
TABLE 85.AMERICORD: OPERATING SEGMENTS
TABLE 86.CRYO-CELL INTERNATIONALS: PRODUCT PORTFOLIO
TABLE 87.CHINA CORD BLOOD CORPORATION: COMPANY SNAPSHOT
TABLE 88.CHINA CORD BLOOD CORPORATION: OPERATING SEGMENTS
TABLE 89.CORD BLOOD AMERICA: COMPANY SNAPSHOT
TABLE 90.CORD BLOOD AMERICA: OPERATING SEGMENTS
TABLE 91.CORDLIFE GROUP LIMITED: COMPANY SNAPSHOT
TABLE 92.CORDLIFE GROUP LIMITED: OPERATING SEGMENTS
TABLE 93.CORDLIFE: PRODUCT PORTFOLIO
TABLE 94.CORDLIFE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 95.CRYO-CELL INTERNATIONAL INC.: COMPANY SNAPSHOT
TABLE 96.CRYO-CELL INTERNATIONALS: OPERATING SEGMENTS
TABLE 97.CRYO-CELL INTERNATIONALS OFFERS FOLLOWING SERVICES:CRYO-CELL INTERNATIONALS: PRODUCT PORTFOLIO
TABLE 98.ESPERITE: COMPANY SNAPSHOT
TABLE 99.ESPERITE: OPERATING SEGMENTS
TABLE 100.ESPERITE : PRODUCT PORTFOLIO
TABLE 01.LIFECELL: COMPANY SNAPSHOT
TABLE 02.LIFECELL: OPERATING SEGMENTS
TABLE 03.LIFECELL: PRODUCT PORTFOLIO
TABLE 04.MEDIPOST CO. LTD: COMPANY SNAPSHOT
TABLE 05.MEDIPOST CO. LTD: OPERATING SEGMENTS
TABLE 06.MEDIPOST CO. LTD: PRODUCT PORTFOLIO
TABLE 07.MEDIPOST CO. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 01.VIACORD : COMPANY SNAPSHOT
TABLE 02.VITA34 INTERNATIONAL: OPERATING SEGMENTS
TABLE 03.VIACORD: PRODUCT PORTFOLIO
TABLE 04.VITA34 INTERNATIONAL: COMPANY SNAPSHOT
TABLE 05.VITA34 INTERNATIONAL: OPERATING SEGMENTS
TABLE 06.VITA34 INTERNATIONAL: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.TOP PLAYER POSITIONING, 2019
FIGURE 02.COMPARATIVE SHARE ANALYSIS FOR PUBLIC CORD BLOOD BANKS MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 03.COMPARATIVE SHARE ANALYSIS OF PRIVATE CORD BLOOD BANKS MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 04.COMPARATIVE SHARE ANALYSIS OF HYBRID CORD BLOOD BANKS MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 05.COMPARATIVE SHARE ANALYSIS OF CANCER  MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 06.COMPARATIVE SHARE ANALYSIS OF DIABETES MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 07.COMPARATIVE SHARE ANALYSIS OF BLOOD DISEASES MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 08.COMPARATIVE SHARE ANALYSIS OF IMMUNE DISORDERS MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 09.COMPARATIVE SHARE ANALYSIS OF METABOLIC DISORDERS MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 10.COMPARATIVE SHARE ANALYSIS OF OTHERS MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 11.COMPARATIVE SHARE ANALYSIS OF TRANSPLANT MEDICINE MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF REGENERATIVE MEDICINE MARKET BY COUNTRY, 2019 & 2027 (%)

CHINA CORD BLOOD CORPORATION: NET SALES, 2017–2019 ($MILLION) 

CORDLIFE GROUP LIMITED: NET SALES, 2017–2018 ($MILLION) 
CORDLIFE: REVENUE SHARE BY SEGMENT, 2018 (%)
CRYO-CELL INTERNATIONAL: NET SALES, 2016–2018 ($MILLION) 
CRYO CELL INTERNATIONALS: REVENUE SHARE BY SEGMENTS, 2018 (%)
MEDIPOST CO. LTD: NET SALES, 2017–2018 ($MILLION) 
VITA34 INTERNATIONAL: NET SALES, 2017–2018 ($MILLION) 

 
 

In accordance with several interviews conducted with top-level CXOs in the industry, it was analyzed that they agree the stem cell from umbilical cord blood can be effectively used for applications such as regenerative medicine and transplant medicine, and is further anticipated to witness a significant rise with discovery of new related applications, rise in incidences of chronic diseases, and easily available facilities such as testing and storage. 

According to CXOs, increase in economic strength of countries such as Canada as well as rise in healthcare expenditure are expected to drive the market growth during the forecast period. Rapid growth was observed in the adoption of stem cell umbilical cord blood in the healthcare industry. Moreover, hybrid storage service providers are expected to dominate the market during the forecast period, while private providers are expected to grow at the highest CAGR.

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library,  T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The total value of Stem Cell Umbilical Cord Blood market was $ 3,110 million in 2019.

A. The forecast period in the report is from 2020-2027.

A. The market value of Stem Cell umbilical Cord blood market in 2020 was $3,390 million.

A. The base year calculated is 2019 in the report.

A. As per the key industry leaders, rise in incidence of chronic diseases cases , increasing R&D initiatives to develop novel technologies and increasing applications for stem cells will drive the market

A. Rise in R&D efforts by the key players to develop novel therapies in the market is expected to drive the market growth during the forecast period.

A. The growth % of the market is 16.9%.

A. Private cord blood banks segment holds the maximum market share.

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Stem Cell Umbilical Cord Blood Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/m
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library.  T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts